The high cost of PCSK9 inhibitors like Repatha
When the FOURIER trial was published in 2017, cardiologists and lipidologists everywhere hailed it as proof that lowering LDL with PCSK9 inhibitors “saves lives.” But when you actually read the data, not the press releases, it’s hard not to shake your head.
Over a median of 2.2 years, evolocumab (Repatha) reduced nonfatal heart attacks by about 0.9 percent and had no significant impact on death. The absolute risk reduction for all-cause …











![How to prepare for your death [PODCAST]](https://kevinmd.com/wp-content/uploads/Design-1-190x100.jpg)
